Cargando…

Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient

Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary,...

Descripción completa

Detalles Bibliográficos
Autores principales: Samonis, George, Bousmpoukea, Aikaterini, Molfeta, Aristea, Kalkinis, Antonios D., Petraki, Kalliopi, Koutserimpas, Christos, Bafaloukos, Dimitrios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689097/
https://www.ncbi.nlm.nih.gov/pubmed/36428923
http://dx.doi.org/10.3390/diagnostics12112864
_version_ 1784836440202412032
author Samonis, George
Bousmpoukea, Aikaterini
Molfeta, Aristea
Kalkinis, Antonios D.
Petraki, Kalliopi
Koutserimpas, Christos
Bafaloukos, Dimitrios
author_facet Samonis, George
Bousmpoukea, Aikaterini
Molfeta, Aristea
Kalkinis, Antonios D.
Petraki, Kalliopi
Koutserimpas, Christos
Bafaloukos, Dimitrios
author_sort Samonis, George
collection PubMed
description Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary, disorders from the upper GI tract are rare. Such a case of delayed nivolumab induced severe gastritis in a 53-year-old Caucasian female patient suffering metastatic melanoma is described. The patient’s symptoms from the upper GI tract began 4 months after nivolumab treatment initiation. The diagnosis was based on imaging, including PET/CT, endoscopical and pathological findings. The side effect was successfully treated with prolonged administration of proton pump inhibitors and corticosteroids. There are only a few cases of immune check point inhibitors (ICPis) induced upper GI tract disorders, while it seems that the symptoms from nivolumab induced upper GI tract damages appear later than those reported in the lower part. Nivolumab, among other side effects, may cause severe gastritis. Hence, this pathological entity should be included in the list of this drug’s side effects.
format Online
Article
Text
id pubmed-9689097
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96890972022-11-25 Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient Samonis, George Bousmpoukea, Aikaterini Molfeta, Aristea Kalkinis, Antonios D. Petraki, Kalliopi Koutserimpas, Christos Bafaloukos, Dimitrios Diagnostics (Basel) Case Report Nivolumab, an anti-PD-1 check point inhibitor, is an immunotherapeutic agent, representing a major step in the treatment of melanoma. However, its use is associated with severe toxicities. Among them, gastrointestinal (GI) disorders from the lower GI tract have been widely reported. On the contrary, disorders from the upper GI tract are rare. Such a case of delayed nivolumab induced severe gastritis in a 53-year-old Caucasian female patient suffering metastatic melanoma is described. The patient’s symptoms from the upper GI tract began 4 months after nivolumab treatment initiation. The diagnosis was based on imaging, including PET/CT, endoscopical and pathological findings. The side effect was successfully treated with prolonged administration of proton pump inhibitors and corticosteroids. There are only a few cases of immune check point inhibitors (ICPis) induced upper GI tract disorders, while it seems that the symptoms from nivolumab induced upper GI tract damages appear later than those reported in the lower part. Nivolumab, among other side effects, may cause severe gastritis. Hence, this pathological entity should be included in the list of this drug’s side effects. MDPI 2022-11-18 /pmc/articles/PMC9689097/ /pubmed/36428923 http://dx.doi.org/10.3390/diagnostics12112864 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Samonis, George
Bousmpoukea, Aikaterini
Molfeta, Aristea
Kalkinis, Antonios D.
Petraki, Kalliopi
Koutserimpas, Christos
Bafaloukos, Dimitrios
Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
title Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
title_full Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
title_fullStr Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
title_full_unstemmed Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
title_short Severe Gastritis Due to Nivolumab Treatment of a Metastatic Melanoma Patient
title_sort severe gastritis due to nivolumab treatment of a metastatic melanoma patient
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9689097/
https://www.ncbi.nlm.nih.gov/pubmed/36428923
http://dx.doi.org/10.3390/diagnostics12112864
work_keys_str_mv AT samonisgeorge severegastritisduetonivolumabtreatmentofametastaticmelanomapatient
AT bousmpoukeaaikaterini severegastritisduetonivolumabtreatmentofametastaticmelanomapatient
AT molfetaaristea severegastritisduetonivolumabtreatmentofametastaticmelanomapatient
AT kalkinisantoniosd severegastritisduetonivolumabtreatmentofametastaticmelanomapatient
AT petrakikalliopi severegastritisduetonivolumabtreatmentofametastaticmelanomapatient
AT koutserimpaschristos severegastritisduetonivolumabtreatmentofametastaticmelanomapatient
AT bafaloukosdimitrios severegastritisduetonivolumabtreatmentofametastaticmelanomapatient